ÂÜÀòÂÒÂ×

Prior to co-founding Epalex, Dr. Randall Murphy was senior vice-president at Medkura Pharmaceuticals, a pharmaceutical development company. From 1978-2000, Dr. Murphy was a tenured faculty member at New York University and an adjunct faculty member at Cornell University Medical College in chemistry, neuroscience, and biological psychiatry. Beginning in 2000, he became active as an entrepreneur in the biotechnology/biopharmaceuticals industry, having co-founded several companies, including Achillion Pharmaceuticals (Nasdaq: ACHN), which is now public, and Marinus Pharmaceuticals (Nasdaq: MRNS), a specialty pharmaceutical company focused on epilepsy that raised more than $70 million in venture financing and is now also a public company. Dr. Murphy is an expert in discovery medicinal chemistry and early- to late-stage pharmaceutical development. He is the youngest graduate of the University of Southern California and is a recipient of the Presidential Fellowship from New York University. Dr. Murphy holds a Ph.D. in chemistry from the University of California, Los Angeles. He is the author of more than 180 research publications and an inventor on 15 issued patents.